Physician profile
Daniel Lebovic
NPI 1740302850
$351,662.96
in general payments reported to CMS, 2019-2025
36 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $47K · 2021: $62K · 2022: $56K · 2023: $43K · 2024: $24K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Consulting Fee: $4,341 · Travel and Lodging: $1,306 · Food and Beverage: $1,007 · Education: $14.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,390.00 |
| Consulting Fee | $4,341.00 |
| Travel and Lodging | $1,306.08 |
| Food and Beverage | $1,006.87 |
| Education | $14.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $97,808.42 | 2019-2025 | |
| Amgen INC. | $91,320.61 | 2019-2024 | Nplate |
| Celgene Corporation | $52,846.91 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40,619.07 | 2019-2022 | |
| Abbvie INC. | $31,559.04 | 2019-2024 | |
| Genentech USA, INC. | $20,485.21 | 2019-2025 | Lunsumio, Columvi, Polivy |
| Pharmaessentia USA Corporation | $8,785.00 | 2024-2025 | Besremi |
| Epizyme, INC. | $6,250.00 | 2020-2021 | |
| Tg Therapeutics, INC. | $562.50 | 2021 | |
| Glaxosmithkline, LLC. | $253.12 | 2022-2025 | Zejula, Jemperli, Blenrep |
| Janssen Biotech, INC. | $228.64 | 2019-2024 | Tecvayli |
| Adaptive Biotechnologies Corporation | $137.00 | 2022-2023 | Clonoseq |
| Astrazeneca Pharmaceuticals Lp | $113.45 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $96.55 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93.45 | 2019-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $73.07 | 2019 | |
| Merck Sharp & Dohme LLC | $48.10 | 2019-2024 | Keytruda, Welireg |
| Eisai INC. | $46.06 | 2019-2024 | |
| Pfizer INC. | $45.29 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $32.64 | 2019 | |
| Exelixis INC. | $29.37 | 2019 | |
| Kyowa Kirin, INC. | $26.35 | 2019 | |
| Gilead Sciences, INC. | $22.89 | 2025 | Trodelvy |
| Sobi, INC | $21.06 | 2024 | |
| Genmab U.S., INC. | $18.57 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $15.50 | 2025 | |
| Astellas Pharma US INC | $14.29 | 2023 | Xospata |
| Incyte Corporation | $11.80 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lebovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.